

let-7 Overexpression Leads to an Increased Fraction of Cells in G₂/M, Direct Down-regulation of Cdc34, and Stabilization of Wee1 Kinase in Primary Fibroblasts^{*§}

Received for publication, January 5, 2009

Published, JBC Papers in Press, January 6, 2009, DOI 10.1074/jbc.C900002200

Aster Legesse-Miller[†], Olivier Elemento^{‡§}, Sarah J. Pfau[‡], Joshua J. Forman[‡], Saeed Tavazoie^{‡§}, and Hilary A. Collier^{†#1}

From the [†]Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544 and the [§]Lewis Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey 08544

microRNAs play a critically important role in a wide array of biological processes including those implicated in cancer, neurodegenerative and metabolic disorders, and viral infection. Although we have begun to understand microRNA biogenesis and function, experimental demonstration of their functional effects and the molecular mechanisms by which they function remains a challenge. Members of the *let-7/miR-98* family play a critical role in cell cycle control with respect to differentiation and tumorigenesis. In this study, we show that exogenous addition of *pre-let-7* in primary human fibroblasts results in a decrease in cell number and an increased fraction of cells in the G₂/M cell cycle phase. Combining microarray techniques with DNA sequence analysis to identify potential *let-7* targets, we discovered 838 genes with a *let-7* binding site in their 3'-untranslated region that were down-regulated upon overexpression of *let-7b*. Among these genes is *cdc34*, the ubiquitin-conjugating enzyme of the Skp1/cullin/F-box (SCF) complex. Cdc34 protein levels are strongly down-regulated by *let-7* overexpression. Reporter assays demonstrated direct regulation of the *cdc34* 3'-untranslated region by *let-7*. We hypothesized that low Cdc34 levels would result in decreased SCF activity, stabilization of the SCF target Wee1, and G₂/M accumulation. Consistent with this hypothesis, small interfering RNA-mediated down-regulation of Wee1 reversed the G₂/M phenotype induced by *let-7* overexpression. We conclude that Cdc34 is a functional target of *let-7* and that *let-7* induces down-regulation of Cdc34, stabilization of the Wee1 kinase, and an increased fraction of cells in G₂/M in primary fibroblasts.

^{*} This work was supported in part by National Institutes of Health Grant R01 GM081686. This work was also supported in part by Grant 2007RSG19572 from the PhRMA Foundation (to H. A. C.) and by National Institutes of Health Grant P50 GM071508 from the NIGMS Center of Excellence (to H. A. C., A. L. and S. T.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[§] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental text, two supplemental figures, and three supplemental tables.

¹ The Milton E. Cassel scholar of the Rita Allen Foundation. To whom correspondence should be addressed. Tel.: 609-258-8466; Fax: 609-258-1704; E-mail: hcollier@princeton.edu.

miRNAs² are non-coding, single-stranded, conserved RNAs of ~22 nucleotides that function as gene regulators (1). miRNAs have emerged as central post-transcriptional negative regulators and have been implicated in a wide array of biological processes including cell cycle control. In metazoans, individual miRNAs can down-regulate hundreds of mRNA targets by interacting with partially complementary sequences within their 3'-untranslated region (3'-UTR) (2, 3).

The *let-7* miRNA was originally discovered in *Caenorhabditis elegans* as a switch gene induced as cells exit the cell cycle when *C. elegans* reach their adult stage (4). In humans and mouse, like *C. elegans*, the expression of *let-7* is barely detectable in embryonic developmental stages but increases after differentiation and in mature tissue (5). *let-7* family members have been implicated as tumor suppressors. Some of the 12 members of the *let-7* family map onto genomic regions altered or deleted in human tumors (6, 7). Further, members of the *let-7* family of miRNAs are consistently down-regulated in lung and colon cancer (8–10). In lung cancers, low levels of *let-7* correlated with shorter survival after resection (9). Decreased *let-7* levels in tumors are associated with elevated levels of Ras, which contains several *let-7* binding sites within its 3'-UTR (8). *let-7* expression is reduced in mammary progenitor cells (11) and breast cancer tumor-initiating cells (12), and enforced *let-7* expression induces loss of self-renewing cells (11). During mammary epithelial cell differentiation, Ras affects self-renewal, whereas a different *let-7* target, HMGA2, contributes to differentiation, thereby emphasizing the importance of identifying multiple miRNA targets to understand their functions (12). In this report, we draw attention to a novel *let-7* target gene, Cdc34, and demonstrate a context in which it may play a functional role.

EXPERIMENTAL PROCEDURES

Cell Culture, Antibodies, and Reagents—Human primary fibroblasts were maintained in FGM-2 (Hyclone, Thermo Fisher Scientific) or Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (Hyclone, Thermo Fisher Scientific) and 100 μg/ml penicillin and streptomycin (Invitrogen). HEK293 cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Anti-Glyceraldehyde-3-phosphate dehydrogenase (AbCam), anti-Cdc34 (H-81) (Santa Cruz Biotechnology), anti-Wee1 (B11) (Santa Cruz Biotechnology), anti-Cdc2-Tyr¹⁵-p (Cell Signaling Technology), and horseradish peroxidase-conjugated anti-rabbit and anti-mouse IgG antibodies (GE Healthcare) were purchased.

Transfection and RNA Interference—Reverse transfection of fibroblasts was performed in 6-well plates. To prepare complexes, 50 nM pre- or anti-miR or negative control RNAs (Ambion) or siRNAs (see supplemental data) were combined with 4 μl of Oligofectamine transfection reagent (Invitrogen) and incubated in a total volume of 200 μl of Opti-MEM (Invitrogen) at room temper-

² The abbreviations used are: miRNA, microRNA; pre-miR, pre-miRNA; UTR, untranslated region; SCF, Skp1/cullin/F-box; siRNA, small interfering RNA; LCS, *let-7b* complementary site; E2, ubiquitin-conjugating enzyme; WT, wild type.

ature for 20 min. A trypsinized cell suspension was mixed with the Oligofectamine/RNA complex and plated (120,000 cells/well). After 24 h, the medium was changed to appropriate medium, and the samples were assayed at the indicated time points. Transfection was performed in duplicate, and the average and standard error of three independent experiments were calculated.

Alamar Blue Assay for Cell Viability/Proliferation—In 96-well plates, 5,000 cells/well were transfected with 50 nM pre- or anti-miR or negative control RNAs combined with 0.5 μ l of Oligofectamine. After 4 h of incubation at 37 °C, growth medium plus serum for a final concentration of 10% was added. At the indicated time points, the percentage of Alamar blue (Invitrogen) reduced by the cells was determined according to the manufacturer's protocols. Transfection was performed in quadruplicate, and the average and standard error were calculated. Similar results were found by counting live cells by hemacytometry.

Flow Cytometry—Cells were trypsinized and fixed with 70% ethanol overnight at 4 °C. Cells were treated with 100 μ g/ml RNase A (Roche Diagnostics) and 50 μ g/ml propidium iodide (Sigma). Propidium iodide fluorescence was monitored with FACSCalibur flow cytometry (BD Biosciences). At least 20,000 cells were collected and analyzed with CellQuest software (BD Biosciences). Cell cycle distributions were calculated with ModFit LT software using the Watson Pragmatics algorithm.

Immunoblot Analysis—Total cellular protein was loaded onto SDS-polyacrylamide gels, electrophoresed, and electrotransferred to polyvinylidene fluoride membranes (PerkinElmer Life Sciences). Following electrotransfer, the membrane was blocked for 1 h and then incubated with primary antibody overnight at 4 °C. Visualization of the protein signal was achieved with horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence (GE Healthcare).

Luciferase Reporter Assay—For *let-7* target validation, HEK293 cells were grown to a cell density of 60–70% in 24-well dishes and then transiently transfected with 0.5 μ g of either experimental or control firefly luciferase plasmids, 0.5 μ g of pRL-CMV (*Renilla* luciferase plasmid, Promega), and 50 nM *pre-let-7* or a control pre-miR using Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfection, cells were harvested, and luciferase activity was measured with a GloMax™ 96 microplate luminometer (Promega). Transfection was performed in duplicate, and luciferase activity was measured in triplicate.

RESULTS

***Pre-let-7b* Transfection Results in a Decrease in Cell Proliferation and an Increased Fraction of Cells in G_2/M Phase**—*let-7* is reduced in lung tumors as compared with adjacent normal tissue (9, 10, 13, 14). In primary fibroblasts, we observed an approximately two-thirds reduction in *let-7b* expression levels in dividing cells as compared with quiescent cells.³ To better understand the role of *let-7* in the cell cycle of primary cells, we transfected asynchronously growing fibroblasts with miRNA precursor molecules for *let-7b*, *let-7c*, or a negative control. Fibroblasts transfected with *pre-let-7b* or *pre-let-7c* exhibited an inhibition of cell growth as compared with those transfected with the negative control at 72

and 96 h after transfection (Fig. 1A). Flow cytometry-based cell cycle analysis revealed a trend toward an accumulation of cells in G_2/M in *pre-let-7b*-transfected primary fibroblasts (Fig. 1C). These results suggest that *let-7* may play a central role in cell proliferation in normal primary fibroblasts.

To further investigate the role of *let-7* in cell cycle regulation, we monitored the cell cycle distribution of *pre-let-7*-transfected cells during synchronization by serum withdrawal and subsequent stimulation to re-enter the cell cycle. Transfection with *pre-let-7b* or another *let-7* family member (*pre-let-7c*) led to a decrease in cell number as compared with cells transfected with control pre-miR (Fig. 1B). Moreover, cells with added *pre-let-7b* tended to accumulate in the G_2/M phase after serum restimulation ($p = 0.0004$ and $p = 0.015$, at 24 and at 36 h, respectively) (Fig. 1D). Conversely, anti-*let-7b*, an RNA that acts as a competitive inhibitor of *let-7b*, caused a statistically significant increase in cell number as compared with a control anti-miR (Fig. 1E). These results suggest that *let-7* causes a decrease in cell number and an increase in the fraction of cells in the G_2/M phase.

Microarray Analysis and Identification of Possible *let-7* Targets—To gain greater insight into the specific genes targeted by *let-7* that may cause the observed phenotypic effects on the cell cycle, we used microarrays to compare the global gene expression profiles of fibroblasts transfected with *pre-let-7b* with those transfected with a negative control as described above. At each time point, beginning at 24 h after transfection, cells transfected with a negative control pre-miR were compared with cells transfected with *pre-let-7b* (see supplemental data for details). Based on their expression profile, genes were clustered into five groups using the *k*-means clustering algorithm (Fig. 2A). The genes in clusters 2 and 4 were consistently down-regulated by *pre-let-7b* and showed moderate and strong down-regulation, respectively. Although the *let-7* seed match (UACCUC) is present in the 3'-UTR of ~16% of the clustered genes, it is present in 32% of genes in cluster 4 ($p < 10^{-25}$) and in 18% of genes in cluster 2 ($p \sim 0.002$) (Fig. 2A). These findings validate our assumption that *bona fide let-7* targets can be identified by microarray (15, 16).

To identify potential *let-7* targets, we looked for genes consistently down-regulated in the presence of *let-7* (*i.e.* genes within cluster 2 or 4) that also contain at least one *let-7* recognition site within their 3'-UTR, resulting in 838 genes (supplemental Table 1). The 838 genes within this list were enriched for 19 terms within the Gene Ontology data base at $p < 10^{-4}$, including developmental process, protein localization, post-translational protein modification, and ubiquitin modification.

let-7* Negatively Regulates the E2 Ubiquitin-conjugating Enzyme *Cdc34—We selected *cdc34*, a *let-7* target that was strongly down-regulated with *pre-let-7b* transfection in our microarray experiments (Fig. 2A), for further analysis. *Cdc34* is an E2 ubiquitin-conjugating enzyme that targets multiple cell cycle regulators for proteasome-mediated degradation as part of the Skp1/cullin/F-box (SCF) complex (17). Thus, down-regulation of *Cdc34* by *let-7* is consistent with our finding that *let-7* targets are enriched in gene products involved in the addition of ubiquitin to target proteins. Down-regulation of *Cdc34* could be an important contributor to the cell cycle changes observed with *pre-let-7b* overexpression.

³ A. Legesse-Miller and H. A. Collier, unpublished data.




FIGURE 1. High levels of *let-7* results in reduced cell proliferation and G_2/M arrest in asynchronously and synchronously dividing fibroblasts, whereas anti-*let-7* results in increased proliferation. A and B, primary fibroblasts transfected with a negative control (NC) pre-miR, *pre-let-7b*, or *pre-let-7c* were monitored using Alamar blue at the indicated time points after transfection. The asterisks indicate statistical significance as compared with the negative control pre-miR. (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$). A, the addition of *pre-let-7b* or *pre-let-7c* resulted in fewer cells in asynchronously dividing primary fibroblasts at 72 and 96 h after transfection. B, cells were monitored at 24 h after transfection, at 36 h after serum withdrawal, then at 12, 24, and 36 h after serum stimulation. Transfection of *let-7b* or *let-7c* as compared with a negative control pre-miR resulted in fewer cells at 24 and 36 h after stimulation. C and D, cell cycle analysis of asynchronous (C) or synchronized (D) cells. An increase in the number of cells in the G_2/M phase of the cell cycle was observed, which reached statistical significance in cells 24 and 36 h after serum stimulation. E, primary fibroblasts transfected with an anti-miR control or anti-*let-7b* were monitored with Alamar blue. Asterisks are as indicated in A and B. In synchronized cells, increased cell number was observed at 24 and 36 h after serum stimulation.

To assess the effects of *pre-let-7b* on *Cdc34* protein levels, we transfected fibroblasts with *pre-let-7b* and then synchronized them by serum withdrawal followed by G_1/S arrest by hydroxyurea. The hydroxyurea was then washed out, and the cells were stimulated to enter the cell cycle. Under these conditions, *Cdc34* protein levels decreased with *pre-let-7b* transfection as compared with samples transfected with a negative control (Fig. 2B). By 24 h after transfection, *Cdc34* protein levels had dropped significantly, and the levels continued to decline through 24 h of restimulation

(Fig. 2B). In asynchronously growing cells, *Cdc34* levels decreased with *pre-let-7b* transfection, and the levels continued to decline for 96 h after transfection (data not shown). As a control, we also monitored the levels of the previously reported *let-7* target, Ras, using an antibody that recognizes both N-Ras and K-Ras and an antibody to N-Ras (8). Under both the asynchronous and the synchronous protocols, *pre-let-7b* transfection led to a larger and more rapid decrease in *Cdc34* levels than in Ras protein levels. *Cdc34* was also down-regulated by *let-7b* overexpression in A549 (lung) and HepG2 (liver) cancer cells (supplemental Fig. S2). Moreover, *cdc34* is also down-regulated at the transcript level in A549 and HepG2 cells when *let-7* is overexpressed (18).

To determine whether *let-7* directly regulates *cdc34* via recognition sites in its 3'-UTR, we established a luciferase reporter system. As positive controls, a firefly luciferase reporter vector containing the *let-7b* miRNA complementary sequence (LCS) and a vector with the *let-7* complementary sequence containing *let-7* seed mutations (Fig. 2C, *LCSm*) were generated from the pMIR-REPORT plasmid. As expected, firefly luciferase activity was reduced for LCS as compared with the pMIR-REPORT control empty vector, whereas the mutated version was less strongly regulated. Co-transfection of LCS with *pre-let-7b* resulted in further reduction of luciferase activity to background levels (Fig. 2C).

Having confirmed that the luciferase assay responds to *let-7*, we then tested reporters in which the 3'-UTR of *cdc34* was inserted downstream of firefly luciferase. The 3'-UTR of *cdc34* contains conserved *let-7* seed matches at positions 27–33 (site 1) and 68–77 (site 2) (*CDC34*-WT). Reporters containing mutations in the *let-7* seed at site 1 (*CDC34*-m1), site 2 (*CDC34*-m2), and both sites (*CDC34*-m1&m2) were also tested for luciferase reporter activity (Fig. 2C). Endogenous *let-7* reduced luciferase activity in plasmids containing the *CDC34* 3'-UTR by about 40%. Transfection of a *CDC34*-m1&m2 vector resulted in luciferase activity at levels similar to the control plasmid in the presence or absence of exogenous *let-7*, demonstrating specific down-regulation of reporter activity by *let-7* through the *cdc34* 3'-UTR. Lucif-




FIGURE 2. Functional effects of *let-7b* overexpression. *A*, microarray analysis of gene transcript level changes associated with *let-7b*. Cells transfected with *let-7* pre-miR or a negative control pre-miR were compared at 24 h after transfection, 36 h of serum withdrawal, and 12, 24, and 36 h of restimulation by hybridization to whole genome microarrays. The \log_2 of the ratio of expression in *let-7b* to negative control samples was used to cluster the genes using *k*-means clustering, and this ratio is shown with yellow indicating high expression in *let-7b*-transfected cells and blue indicating high expression in negative control cells. Genes in clusters 2 and 4 are consistently down-regulated upon *pre-let-7b* transfection, and some of these genes may be direct *let-7* targets. *B*, *pre-let-7* induction leads to down-regulation of Cdc34 protein levels in primary fibroblasts. Fibroblasts were transfected with *pre-let-7b* (+) or negative control pre-miR (-). Cells were synchronized by serum withdrawal (24 h) followed by hydroxyurea (HU) treatment (18 h), and then hydroxyurea was washed out to stimulate the cells to re-enter the cell cycle. Samples were taken at the indicated time points after serum stimulation. High levels of *let-7b* resulted in down-regulation of Cdc34 protein levels. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. *C*, *let-7* directly regulates the *cdc34* 3'-UTR through two *let-7* recognition sites. Luciferase reporter constructs containing a mature LCS, a mutated *let-7b* (LCSm), the 3'-UTR of wild type *cdc34* (CDC34-WT), or the *cdc34* 3'-UTR with mutations in the *let-7* binding sites (CDC34-m1&m2, CDC34-m1, and CDC34-m2) were cloned downstream of a firefly luciferase reporter gene and transfected with *pre-let-7b* or negative control (NC) into HEK-293 cells. A second vector with a *Renilla* luciferase reporter was used for normalization of transfection efficiency. A mature LCS was used as a positive control. A portion of the *cdc34* 3'-UTR was sufficient to direct down-regulation of luciferase by endogenous and exogenous *let-7*. Mutating both of the *let-7* recognition sites within the *cdc34* 3'-UTR was sufficient to abrogate the effect, demonstrating that these two sites are the functionally important sequences within the *cdc34* 3'-UTR. *D*, *let-7b*-mediated G_2/M arrest is partially rescued by an siRNA to Wee1. Primary fibroblasts were transfected with an siRNA to Wee1 or left untreated (cont.) and analyzed by Western blot. Introduction of an siRNA to Wee1 resulted in reduced Wee1 levels 24 h after transfection (left). Asynchronously growing cells were transfected with negative control pre-miR or *pre-let-7b* and either an siRNA to luciferase (siLuc) or an siRNA to Wee1 (siWee1). Cells were collected 24 h after transfection and analyzed by flow cytometry for cell cycle (right). At 24 h after transfection, the siRNA to Wee1 resulted in an increase in the number of cells in S phase. *Pre-let-7b*-transfected cells contained a higher fraction of cells in the G_2/M phase of the cell cycle. In cells transfected with both *pre-let-7b* and an siRNA to Wee1, the S and G_2/M fractions resembled those in control cells (NC + siLuc) (***) indicates G_2/M fraction in *let-7b* + siLuc versus *let-7b* + siWee1, $p < 0.001$).

erase activity from vectors with mutations in a single site revealed that both sites contribute to down-regulation of Cdc34 by *let-7b* and that site 1 results in stronger down-regulation than site 2.

Wee1 Partially Rescues *let-7*-mediated G_2/M Arrest—Cdc34 controls progression into mitosis partially by degrading the Wee1 kinase, which adds inhibitory phosphates to cyclin-dependent kinases (Cdc2) (19). We hypothesized that *let-7* overexpression may result in reduced Cdc34 levels and Wee1 stabilization. This would be expected to result in the increased number of cells in G_2/M phase observed upon *let-7b* overexpression (Fig. 1, C and D) because Wee1 degradation in G_2 is required for progression into mitosis (20). Anti-*let-7b* would result in reduced levels of Wee1 and is thus predicted to hasten the cell cycle and result in an increased proliferation rate (Fig. 1E). To test this hypothesis, we monitored Wee1 levels in *let-7b*-overexpressing cells. Primary fibroblasts were transfected with *pre-let-7b* or control pre-miRNA. Western blot analysis revealed higher Wee1 levels in cells transfected with *pre-let-7b* (Fig. 2B). Introduction of *pre-let-7b* into A549, but not HepG2 cancer cells, also resulted in Wee1 stabilization (supplemental Fig. S2). We then determined whether stabilization of Wee1 in *pre-let-7b*-transfected primary fibroblasts leads to elevated levels of the Wee1 substrate Cdc2-Tyr¹⁵-p. Western blot analysis using the phosphospecific Cdc2-Tyr¹⁵-p antibody detected a higher level of Cdc2-Tyr¹⁵-p in *pre-let-7b*-transfected cells (+) as compared with control pre-miR-transfected cells (-) (Fig. 2B).

To assess the functional effect of Wee1 stabilization, we transfected asynchronous fibroblasts with *pre-let-7b* or a negative control in the presence or absence of an siRNA to Wee1 or luciferase as a control. Twenty-four hours after transfection, the Wee1 siRNA resulted in reduced Wee1 levels (Fig. 2D, left) and an increased fraction of cells in S phase (Fig. 2D, right). Cells transfected with *pre-let-7b* exhibited a sig-

nificant increase in the fraction of cells in the G₂/M phase of the cell cycle as compared with cells transfected with a negative control (Fig. 2D). When cells were co-transfected with *pre-let-7b* and an siRNA to Wee1, the fractions of cells in S phase and in G₂/M phase of the cell cycle were similar to the levels in cells transfected with the negative control (Fig. 2D). Thus, we bypass the *let-7*-mediated block by decreasing Wee1 levels. These results are consistent with a model in which *let-7* induces G₂/M arrest via down-regulation of Cdc34 and subsequent inhibition of Cdc2 via Wee1 stabilization.

DISCUSSION

Members of the *let-7* miRNA family are induced under a variety of conditions in which cells exit the cell cycle and are down-regulated in the context of inappropriate proliferation. The *let-7* miRNA was originally discovered in *C. elegans* as a switch gene induced as cells exit the cell cycle when *C. elegans* reach their adult stage (4). In humans and mouse, like *C. elegans*, the expression of *let-7* is barely detectable in embryonic stages but increases after differentiation and in mature tissue (5). In contrast, *let-7* is frequently underexpressed in lung tumors (9, 10, 13) and in colon cancer cell lines (7).

Overexpression of the *let-7* miRNA contributes to exit from the proliferative cell cycle with the specific effects dependent upon cell type. In the A549 lung cancer cell line, *let-7* overexpression suppresses proliferation (18) and reduces colony-forming capability (9), whereas inhibiting *let-7* results in more cells (18). Similarly, transfection of *let-7* into colorectal cancer cells causes a dose-dependent decrease in cell number and decreased plating efficiency (7). In HepG2 cells, introduction of *let-7* results in an accumulation of cells in G₀/G₁ (18). In a mouse mammary epithelial cell line, *let-7* overexpression induces loss of self-renewing cells from the population (11). We show here that introduction of *pre-let-7* into normal fibroblasts leads to reduced cell number and to G₂/M cell cycle arrest. Previous studies on the functional effects of *let-7* have focused on the targets Ras, HMGA2, and c-Myc (8, 21–23). We show here that Cdc34, the ubiquitin-conjugating enzyme of the SCF complex, is a direct *let-7* target through Western blotting and reporter assays. The results demonstrate a mechanistic link between *let-7* and proteasome-mediated protein degradation. Because many cell cycle proteins are targeted for ubiquitination and degradation by the SCF complex, cell type differences in the role of different direct or indirect *let-7* cell cycle targets or in the targets of the SCF could result in the cell type specificity observed in the phenotypic consequences of regulating *let-7* levels. In primary fibroblasts, we show that an increase in *let-7* levels results in an increased fraction of cells in G₂/M, and this phenotype correlates with stabilization of the SCF target, Wee1 kinase, as Cdc34 levels decline. In A549 and HepG2 cells, *let-7* overexpression also leads to down-regulation of Cdc34, but in these cells, there is an accumulation of cells in G₀/G₁ phase (supplemental Fig. S2), similar to findings reported by Jonson *et al.* (18) for HepG2 cells. Different *let-7* targets, or the same targets in different cellular environments, may contribute to the cell cycle phenotype in cancer cells. In A549 cells, Cdc34 down-regulation by *let-7* overexpression resulted in Wee1 protein stabilization, suggesting that a similar regulatory mechanism may exist in some cancer cells. We hypothesize that, in some types of cancer cells, low *let-7* levels may

result in higher levels of Cdc34. This could cause faster proteolysis of cell cycle proteins, thus hastening cell cycle transitions and potentially contributing to the increased genomic instability of cancer cells. Indeed, future studies could test whether this represents part of the basis for the association between low *let-7* levels and poor prognosis (9, 10).

Our findings suggest a mechanistic link between the *let-7* family of miRNAs, G₂/M arrest in primary fibroblasts, and the Cdc34-mediated proteolytic degradation of Wee1 kinase. We anticipate that unraveling the molecular mechanisms by which miRNAs mediate their effects will allow us to decipher the central regulatory role of miRNAs in many fundamental biological processes.

Acknowledgments—We thank the following colleagues at Princeton University: Jessica Buckles, Donna Storton, Christina DeCoste, Curtis Huttenhower, Erin Haley, Jay Im, Peter Wei, John Matese, Yibin Kang, Manav Korpal, Amy Caudy, Leonid Kruglyak and the Collier laboratory.

REFERENCES

- Bartel, D. P. (2004) *Cell* **116**, 281–297
- Lewis, B. P., Burge, C. B., and Bartel, D. P. (2005) *Cell* **120**, 15–20
- Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., and Johnson, J. M. (2005) *Nature* **433**, 769–773
- Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., Rougvié, A. E., Horvitz, H. R., and Ruvkun, G. (2000) *Nature* **403**, 901–906
- Lee, Y. S., Kim, H. K., Chung, S., Kim, K. S., and Dutta, A. (2005) *J. Biol. Chem.* **280**, 16635–16641
- Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., and Croce, C. M. (2004) *Proc. Natl. Acad. Sci. U. S. A.* **101**, 2999–3004
- Akao, Y., Nakagawa, Y., and Naoe, T. (2006) *Biol. Pharm. Bull.* **29**, 903–906
- Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., and Slack, F. J. (2005) *Cell* **120**, 635–647
- Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., Mitsudomi, T., and Takahashi, T. (2004) *Cancer Res.* **64**, 3753–3756
- Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., Calin, G. A., Liu, C. G., Croce, C. M., and Harris, C. C. (2006) *Cancer Cell* **9**, 189–198
- Ibarra, I., Erlich, Y., Muthuswamy, S. K., Sachidanandam, R., and Hannon, G. J. (2007) *Genes Dev.* **21**, 3238–3243
- Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J., and Song, E. (2007) *Cell* **131**, 1109–1123
- Inamura, K., Togashi, Y., Nomura, K., Ninomiya, H., Hiramatsu, M., Satoh, Y., Okumura, S., Nakagawa, K., and Ishikawa, Y. (2007) *Lung Cancer* **58**, 392–396
- Taipale, J., and Beachy, P. A. (2001) *Nature* **411**, 349–354
- Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P., and Bartel, D. P. (2008) *Nature* **455**, 64–71
- Selbach, M., Schwanhauss, B., Thierfelder, N., Fang, Z., Khanin, R., and Rajewsky, N. (2008) *Nature* **455**, 58–63
- Willems, A. R., Schwab, M., and Tyers, M. (2004) *Biochim. Biophys. Acta* **1695**, 133–170
- Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., Wilson, M., Wang, X., Shelton, J., Shingara, J., Chin, L., Brown, D., and Slack, F. J. (2007) *Cancer Res.* **67**, 7713–7722
- Morgan, D. O. (1995) *Nature* **374**, 131–134
- Michael, W. M., and Newport, J. (1998) *Science* **282**, 1886–1889
- Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R., and Jacks, T. (2007) *Nat. Genet.* **39**, 673–677
- Mayr, C., Hemann, M. T., and Bartel, D. P. (2007) *Science* **315**, 1576–1579
- Sampson, V. B., Rong, N. H., Han, J., Yang, Q., Aris, V., Soteropoulos, P., Petrelli, N. J., Dunn, S. P., and Krueger, L. J. (2007) *Cancer Res.* **67**, 9762–9770